Developer docs
API playgroundTry for free, no card

Search company profiles

Corbus Pharmaceuticals

Full company profile

uuid0002l1s

Namestring
Corbus Pharmaceuticals
Legal namestring
Corbus Pharmaceuticals Holdings, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company headquartered at 500 River Ridge Drive, Norwood, Massachusetts, publicly traded on NASDAQ under ticker CRBP with a market capitalization of approximately $137-178 million. The company employs 51-100 staff and is developing precision therapeutics across two distinct therapeutic verticals: oncology and obesity/metabolic disease. Corbus's core pipeline comprises three clinical-stage assets: CRB-701, a next-generation Nectin-4-targeting antibody drug conjugate (ADC) using site-specific conjugation and a novel linker to deliver monomethyl auristatin E (MMAE), licensed from CSPC Megalith Biopharmaceutical for head and neck squamous cell carcinoma (HNSCC) and cervical cancer indications; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity representing a non-incretin, non-GLP-1 mechanism, licensed from Jenrin Discovery; and CRB-601, an anti-αvβ8 integrin monoclonal antibody designed to block activation of latent TGF-β in the tumor microenvironment, licensed from the University of California San Francisco. The company previously developed lenabasum, a CB2 agonist for inflammatory-fibrotic conditions, but discontinued the program after Phase 3 failures in systemic sclerosis (2020) and dermatomyositis.

Corbus operates a pre-revenue business model funded almost entirely by capital markets. The company has raised approximately $169.5 million through two recent public equity offerings ($94.5M in February 2024 at $19.00/share and ~$75M in October 2025), supplementing earlier financings totaling over $300 million since 2014. As of Q1 2026, the company reported $138.2 million in cash, cash equivalents, and investments, with quarterly operating expenses of approximately $24.3 million and net losses of $20-23 million, providing a runway into 2028. The go-to-market approach contemplates future product sales upon regulatory approval or out-licensing to larger pharmaceutical partners, with the existing CSPC license representing a precedent for such transactions. CRB-701 has received FDA Fast Track designation in both HNSCC and cervical cancer indications, supporting a registrational study path for second-line HNSCC.

The company's competitive positioning rests on differentiated drug design rather than AI or digital capabilities. CRB-701's site-specific conjugation technology aims to deliver an improved therapeutic index versus PADCEV (the incumbent Nectin-4 ADC from Pfizer/Astellas), while CRB-913's peripheral restriction targets an obesity mechanism orthogonal to GLP-1 receptor agonists. Corbus engages institutional investors through conferences (RBC, Jefferies, BTIG) and the medical community through major oncology venues (ASCO 2026, ESMO 2025), supplemented by Key Opinion Leader events with leading HNSCC experts. The leadership team comprises CEO Yuval Cohen, CFO Sean Moran, and recently appointed CBO Nishant Saxena (ex-Evercore Managing Director), with a board chaired by Rachelle Jacques and including Brent Pfeiffenberger (CEO of Century Therapeutics, ex-BMS Head of U.S. Oncology).

Short descriptiontext

Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing precision therapeutics in oncology (CRB-701 Nectin-4 ADC for HNSCC and cervical cancer; CRB-601 anti-αvβ8 antibody) and obesity (CRB-913 oral CB1 inverse agonist), funded primarily through public equity offerings and pre-revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNorwood, United States
HQ citystring
Norwood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, antibody drug conjugates, precision oncology therapeutics, obesity drug development, monoclonal antibody therapy
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals (Oncology and Obesity Therapeutics)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage company developing pipeline of drug candidates (CRB-701, CRB-913, CRB-601) for oncology and obesity indications. Revenue will be generated through product sales upon regulatory approval or through licensing/partnership agreements.

ir.corbuspharma.com
2Licensing and Partnership Deals
TypeLicensing Royalties
Description

Company may enter into licensing agreements for drug candidates, such as the CRB-701 license from CSPC and potential future partnerships to fund development and commercialization.

in.investing.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing drug candidates for precision oncology and obesity. Its core pipeline consists of CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company licenses drug candidates from partners (CSPC, UCSF, Jenrin Discovery) and advances them through clinical trials toward regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 42.9% objective response rate in second-line oropharyngeal squamous cell carcinoma at 3.6 mg/kg dose
+4 more records
Product overview1 text field

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing targeted therapies in precision oncology and obesity. The company's core product portfolio includes CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral CB1 inverse agonist for obesity with a non-incretin mechanism; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company previously developed Lenabasum (CB2 agonist) but discontinued clinical development after Phase 3 trial failures. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. and CRB-601 is in-licensed from UCSF. CRB-913 was developed internally from the company's endocannabinoid platform.

Product and service3 records
1CRB-701
CategoryPrecision Oncology / Antibody Drug Conjugate
Description

Next-generation antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of head and neck squamous cell carcinoma (HNSCC) and cervical cancer. Licensed from CSPC Megalith Biopharmaceutical Co., Ltd., with FDA Fast Track designation for both cancer types. Demonstrated 42.9% ORR in second-line OPSCC and 34.4% in second-line cervical cancer at 3.6 mg/kg dose.

2CRB-913
CategoryObesity Therapeutics / CB1 Receptor Modulator
Description

Highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity, representing a non-GLP-1 and non-incretin mechanism of action for weight loss and long-term weight management. Licensed from Jenrin Discovery, LLC. CANYON-1 Phase 1b trial testing three oral dose cohorts (20mg, 40mg, and 60mg daily).

3CRB-601
CategoryPrecision Oncology / Monoclonal Antibody
Description

Anti-αvβ8 integrin monoclonal antibody designed to block activation of latent TGFβ within the tumor microenvironment for treatment of solid tumors. Being developed in combination with checkpoint inhibitors. Licensed from UCSF with FDA IND clearance.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-02-12
Description

Exclusive licensing agreement granting Corbus rights to develop and commercialize CRB-701 (Nectin-4 targeting ADC) in the United States, Canada, European Union, United Kingdom, and Australia for all oncology indications. CSPC retains rights in China and other territories.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-05-26
Description

Exclusive worldwide license to patent applications relating to humanized antibodies against integrin αvβ8 (CRB-601), including antibody for diagnostic use and related know-how and materials.

3Jenrin Discovery, LLC
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-09-20
Description

Exclusive worldwide license to develop and market cannabinoid compounds (including CRB-913) covered by Jenrin patents for obesity, diabetes, hepatic disorders, and cardiometabolic disorders.

ir.corbuspharma.com
4Kaken Pharmaceutical Co., Ltd.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-01-03
Description

Strategic collaboration to develop and commercialize lenabasum in Japan for systemic sclerosis and dermatomyositis.

ir.corbuspharma.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Pioneer in ADC technology with approved ELAHERE (mirvetuximab). Acquired by AbbVie in 2024, illustrating the strategic exit path for differentiated ADC developers and a relevant benchmark for ADC-focused clinical-stage companies.

TypeEmerging player
Description

Clinical-stage oncology biotech led by Brent Pfeiffenberger (Corbus board member and former BMS oncology SVP). Comparable as a small-cap, public, clinical-stage oncology company developing novel cell therapy and targeted oncology approaches.

TypeDirect peer
Description

Clinical-stage oncology biotech developing next-generation ADCs with proprietary linker and payload platforms. Closely comparable to Corbus as a small-cap, pipeline-focused ADC developer advancing differentiated ADC chemistry toward registrational studies.

TypeOthers
Description

Licensor of CRB-701 to Corbus. Retains China and other territorial rights and continues to develop the parent Nectin-4 ADC program, making it the most directly connected party on asset economics, manufacturing, and global development strategy.

TypeRegional player
Description

Commercial-stage gene therapy biotech whose former subsidiary Jeune Aesthetics employed Corbus CBO Nishant Saxena. Provides a comparable public, US-based small-cap biotech archetype that successfully transitioned from clinical to commercial stage.

TypeBroad incumbent
Description

Markets Mounjaro/Zepbound (tirzepatide), the dominant GLP-1 obesity therapy. Defines the standard of care that CRB-913's non-incretin CB1 mechanism must differentiate against in the obesity indication.

TypeBroad incumbent
Description

Markets PADCEV (enfortumab vedotin), the only approved Nectin-4 targeting ADC. Direct mechanistic competitor to Corbus's lead asset CRB-701 in HNSCC and cervical cancer, and validates the Nectin-4 ADC commercial opportunity at scale.

8Mythic Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing antibody therapeutics for solid tumors using proprietary technology to address resistance to current therapies. Comparable as a small-cap precision oncology developer leveraging novel antibody engineering approaches.

TypeBroad incumbent
Description

Markets Wegovy/Ozempic (semaglutide), the established GLP-1 obesity therapy. Sets the efficacy and safety benchmark against which any non-GLP-1 obesity asset like CRB-913 must demonstrate meaningful clinical differentiation.

TypeBroad incumbent
Description

Global leader in ADC technology (DXd platform behind Enhertu and ifinatamab deruxtecan, a Nectin-4 ADC partnered with Merck). Comparable pipeline of oncology ADCs and a benchmark for next-generation site-specific linker technology that Corbus is emulating.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corbus Pharmaceuticals

Clinical-Stage Biopharmaceuticals (Oncology and Obesity Therapeutics)corbuspharma.com

Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing precision therapeutics in oncology (CRB-701 Nectin-4 ADC for HNSCC and cervical cancer; CRB-601 anti-αvβ8 antibody) and obesity (CRB-913 oral CB1 inverse agonist), funded primarily through public equity offerings and pre-revenue.

What Corbus Pharmaceuticals does

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company headquartered at 500 River Ridge Drive, Norwood, Massachusetts, publicly traded on NASDAQ under ticker CRBP with a market capitalization of approximately $137-178 million. The company employs 51-100 staff and is developing precision therapeutics across two distinct therapeutic verticals: oncology and obesity/metabolic disease. Corbus's core pipeline comprises three clinical-stage assets: CRB-701, a next-generation Nectin-4-targeting antibody drug conjugate (ADC) using site-specific conjugation and a novel linker to deliver monomethyl auristatin E (MMAE), licensed from CSPC Megalith Biopharmaceutical for head and neck squamous cell carcinoma (HNSCC) and cervical cancer indications; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity representing a non-incretin, non-GLP-1 mechanism, licensed from Jenrin Discovery; and CRB-601, an anti-αvβ8 integrin monoclonal antibody designed to block activation of latent TGF-β in the tumor microenvironment, licensed from the University of California San Francisco. The company previously developed lenabasum, a CB2 agonist for inflammatory-fibrotic conditions, but discontinued the program after Phase 3 failures in systemic sclerosis (2020) and dermatomyositis.

Corbus operates a pre-revenue business model funded almost entirely by capital markets. The company has raised approximately $169.5 million through two recent public equity offerings ($94.5M in February 2024 at $19.00/share and ~$75M in October 2025), supplementing earlier financings totaling over $300 million since 2014. As of Q1 2026, the company reported $138.2 million in cash, cash equivalents, and investments, with quarterly operating expenses of approximately $24.3 million and net losses of $20-23 million, providing a runway into 2028. The go-to-market approach contemplates future product sales upon regulatory approval or out-licensing to larger pharmaceutical partners, with the existing CSPC license representing a precedent for such transactions. CRB-701 has received FDA Fast Track designation in both HNSCC and cervical cancer indications, supporting a registrational study path for second-line HNSCC.

The company's competitive positioning rests on differentiated drug design rather than AI or digital capabilities. CRB-701's site-specific conjugation technology aims to deliver an improved therapeutic index versus PADCEV (the incumbent Nectin-4 ADC from Pfizer/Astellas), while CRB-913's peripheral restriction targets an obesity mechanism orthogonal to GLP-1 receptor agonists. Corbus engages institutional investors through conferences (RBC, Jefferies, BTIG) and the medical community through major oncology venues (ASCO 2026, ESMO 2025), supplemented by Key Opinion Leader events with leading HNSCC experts. The leadership team comprises CEO Yuval Cohen, CFO Sean Moran, and recently appointed CBO Nishant Saxena (ex-Evercore Managing Director), with a board chaired by Rachelle Jacques and including Brent Pfeiffenberger (CEO of Century Therapeutics, ex-BMS Head of U.S. Oncology).

Corbus Pharmaceuticals firmographics

Firmographics
Name
Corbus Pharmaceuticals
Legal name
Corbus Pharmaceuticals Holdings, Inc.
Website
https://corbuspharma.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing precision therapeutics in oncology (CRB-701 Nectin-4 ADC for HNSCC and cervical cancer; CRB-601 anti-αvβ8 antibody) and obesity (CRB-913 oral CB1 inverse agonist), funded primarily through public equity offerings and pre-revenue.
Ownership category
akta.pro rank

Corbus Pharmaceuticals industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals (Oncology and Obesity Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage biopharmaceuticals
  • Antibody drug conjugates
  • Precision oncology therapeutics
  • Obesity drug development
  • Monoclonal antibody therapy

Where Corbus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Norwood
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Corbus Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage company developing pipeline of drug candidates (CRB-701, CRB-913, CRB-601) for oncology and obesity indications. Revenue will be generated through product sales upon regulatory approval or through licensing/partnership agreements.
  2. Licensing and Partnership Deals: Company may enter into licensing agreements for drug candidates, such as the CRB-701 license from CSPC and potential future partnerships to fund development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Corbus Pharmaceuticals product offering

Product offering

Core offering

Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing drug candidates for precision oncology and obesity. Its core pipeline consists of CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company licenses drug candidates from partners (CSPC, UCSF, Jenrin Discovery) and advances them through clinical trials toward regulatory approval.

Product overview

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company developing targeted therapies in precision oncology and obesity. The company's core product portfolio includes CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral CB1 inverse agonist for obesity with a non-incretin mechanism; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company previously developed Lenabasum (CB2 agonist) but discontinued clinical development after Phase 3 trial failures. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. and CRB-601 is in-licensed from UCSF. CRB-913 was developed internally from the company's endocannabinoid platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • CRB-701 Next-generation antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of head and neck squamous cell carcinoma (HNSCC) and cervical cancer. Licensed from CSPC Megalith Biopharmaceutical Co., Ltd., with FDA Fast Track designation for both cancer types. Demonstrated 42.9% ORR in second-line OPSCC and 34.4% in second-line cervical cancer at 3.6 mg/kg dose.
  • CRB-913 Highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity, representing a non-GLP-1 and non-incretin mechanism of action for weight loss and long-term weight management. Licensed from Jenrin Discovery, LLC. CANYON-1 Phase 1b trial testing three oral dose cohorts (20mg, 40mg, and 60mg daily).
  • CRB-601 Anti-αvβ8 integrin monoclonal antibody designed to block activation of latent TGFβ within the tumor microenvironment for treatment of solid tumors. Being developed in combination with checkpoint inhibitors. Licensed from UCSF with FDA IND clearance.

Quantifiable outcome

  • 42.9% objective response rate in second-line oropharyngeal squamous cell carcinoma at 3.6 mg/kg dose
  • +4 more outcomes

Companies that use Corbus Pharmaceuticals

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Corbus Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Corbus Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • CSPC Megalith Biopharmaceutical Co., Ltd. (CSPC)coreOEM/ Whitelabel/ Licensing Partner · 12 February 2023Exclusive licensing agreement granting Corbus rights to develop and commercialize CRB-701 (Nectin-4 targeting ADC) in the United States, Canada, European Union, United Kingdom, and Australia for all oncology indications. CSPC retains rights in China and other territories.
  • University of California, San Francisco (UCSF)coreTechnology or Integration · 26 May 2021Exclusive worldwide license to patent applications relating to humanized antibodies against integrin αvβ8 (CRB-601), including antibody for diagnostic use and related know-how and materials.
  • Jenrin Discovery, LLCcoreTechnology or Integration · 20 September 2018Exclusive worldwide license to develop and market cannabinoid compounds (including CRB-913) covered by Jenrin patents for obesity, diabetes, hepatic disorders, and cardiometabolic disorders.
  • Kaken Pharmaceutical Co., Ltd.minorStrategic or Co-development Partner · 3 January 2018Strategic collaboration to develop and commercialize lenabasum in Japan for systemic sclerosis and dermatomyositis.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Corbus Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer in ADC technology with approved ELAHERE (mirvetuximab). Acquired by AbbVie in 2024, illustrating the strategic exit path for differentiated ADC developers and a relevant benchmark for ADC-focused clinical-stage companies.
  • Eli Lilly: Markets Mounjaro/Zepbound (tirzepatide), the dominant GLP-1 obesity therapy. Defines the standard of care that CRB-913's non-incretin CB1 mechanism must differentiate against in the obesity indication.
  • Pfizer (Seagen): Markets PADCEV (enfortumab vedotin), the only approved Nectin-4 targeting ADC. Direct mechanistic competitor to Corbus's lead asset CRB-701 in HNSCC and cervical cancer, and validates the Nectin-4 ADC commercial opportunity at scale.
  • Novo Nordisk: Markets Wegovy/Ozempic (semaglutide), the established GLP-1 obesity therapy. Sets the efficacy and safety benchmark against which any non-GLP-1 obesity asset like CRB-913 must demonstrate meaningful clinical differentiation.
  • Daiichi Sankyo: Global leader in ADC technology (DXd platform behind Enhertu and ifinatamab deruxtecan, a Nectin-4 ADC partnered with Merck). Comparable pipeline of oncology ADCs and a benchmark for next-generation site-specific linker technology that Corbus is emulating.

Emerging players

  • Century Therapeutics: Clinical-stage oncology biotech led by Brent Pfeiffenberger (Corbus board member and former BMS oncology SVP). Comparable as a small-cap, public, clinical-stage oncology company developing novel cell therapy and targeted oncology approaches.
  • Mythic Therapeutics: Clinical-stage biotech developing antibody therapeutics for solid tumors using proprietary technology to address resistance to current therapies. Comparable as a small-cap precision oncology developer leveraging novel antibody engineering approaches.

Direct peers

  • Mersana Therapeutics: Clinical-stage oncology biotech developing next-generation ADCs with proprietary linker and payload platforms. Closely comparable to Corbus as a small-cap, pipeline-focused ADC developer advancing differentiated ADC chemistry toward registrational studies.

Others

  • CSPC Megalith Biopharmaceutical: Licensor of CRB-701 to Corbus. Retains China and other territorial rights and continues to develop the parent Nectin-4 ADC program, making it the most directly connected party on asset economics, manufacturing, and global development strategy.

Regional players

  • Krystal Biotech: Commercial-stage gene therapy biotech whose former subsidiary Jeune Aesthetics employed Corbus CBO Nishant Saxena. Provides a comparable public, US-based small-cap biotech archetype that successfully transitioned from clinical to commercial stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Corbus Pharmaceuticals social profiles

Digital presence

Corbus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corbus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Corbus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corbus Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corbus Pharmaceuticals

What does Corbus Pharmaceuticals do?

Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company developing drug candidates for precision oncology and obesity. Its core pipeline consists of CRB-701, a next-generation Nectin-4 targeting antibody drug conjugate for head and neck squamous cell carcinoma and cervical cancer; CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity; and CRB-601, an anti-αvβ8 monoclonal antibody for solid tumors. The company licenses drug candidates from partners (CSPC, UCSF, Jenrin Discovery) and advances them through clinical trials toward regulatory approval.

Is Corbus Pharmaceuticals a public or private company?

Corbus Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Corbus Pharmaceuticals founded?

Corbus Pharmaceuticals was founded in 2014. It employs 51 to 100 people.

Where is Corbus Pharmaceuticals based?

Corbus Pharmaceuticals is headquartered in Norwood, United States, in the North America region.

How does Corbus Pharmaceuticals make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are licensing and Partnership Deals.

Who are Corbus Pharmaceuticals's main competitors?

Broad incumbents on record are ImmunoGen (AbbVie), Eli Lilly, Pfizer (Seagen), Novo Nordisk and Daiichi Sankyo. Emerging players are Century Therapeutics and Mythic Therapeutics. Mersana Therapeutics is listed as a direct peer. CSPC Megalith Biopharmaceutical is listed as an others. Krystal Biotech is listed as a regional player.

Does Corbus Pharmaceuticals have an API?

No public API is recorded for Corbus Pharmaceuticals.

What industry is Corbus Pharmaceuticals in?

Corbus Pharmaceuticals's product category is Clinical-Stage Biopharmaceuticals (Oncology and Obesity Therapeutics). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchCorbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitorsCorbus Pharmaceuticals Holdings Inc. shares fell 10.81% to $3.01 on Tuesday, marking the fourth consecutive day of losses. The decline occurred amid a rough trading session, with the NASDAQ Composite down 0.74% and the Dow down 1.64%.American Banking and Market NewsCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Target Lowered at MizuhoMizuho lowered its price target for Corbus Pharmaceuticals from $24 to $23, keeping an outperform rating. The stock opened at $3.41, and the company reported a loss of $1.81 per share, missing estimates. The consensus price target is $35.67.MarketWatchCorbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitorsCorbus Pharmaceuticals Holdings Inc. stock fell 14.75% to $3.41 on Thursday, ending a four-day winning streak. The decline occurred amid a broader market downturn, with the NASDAQ Composite down 0.39% and the Dow down 0.36%.Investing.comMizuho cuts Corbus Pharmaceuticals stock price target on model tweaksMizuho lowered its price target on Corbus Pharmaceuticals to $23 from $24, citing model tweaks and a discounted cash flow roll-forward. The company reported Q3 2026 results with operating expenses above estimates due to a $15 million milestone payment to CSPC for CRB-701. Mizuho expects positive first-line data in Q1 2027 to de-risk the drug.MarketWatchCorbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading dayCorbus Pharmaceuticals Holdings Inc. shares rose 1.78% to $4.00 on Wednesday, marking its fourth consecutive day of gains. The NASDAQ Composite and Dow Jones Industrial Average also advanced, with the former up 1.60% and the latter 0.49%.TradingViewRBC Capital maintains Corbus Pharmaceuticals at Outperform, lowers price target to $33 from $36RBC Capital maintained Corbus Pharmaceuticals at Outperform and lowered its price target to $33 from $36, an 8.3% decrease. The price target implies an upside of 739.7% from the Nov 10 close of $3.93.TradingViewWedbush maintains Corbus Pharmaceuticals at Outperform, lowers price target to $27 from $30Wedbush maintained Corbus Pharmaceuticals at Outperform and lowered its price target to $27 from $30, a 10% decrease. The target implies an upside of 587% from the Nov 10 close of $3.93.Investing.comOppenheimer cuts Corbus Pharmaceuticals stock price target to $40Oppenheimer lowered its price target on Corbus Pharmaceuticals to $40 from $48, keeping an Outperform rating. The stock trades at $3.93, down 64% over six months, with a market cap of $81 million. Corbus is scheduled to present Phase 1b results for its '913 program at Obesity Week on November 14, 2026.MarketWatchCorbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading dayCorbus Pharmaceuticals Holdings Inc. shares rose 11.65% to $3.93 on Tuesday, outperforming a weak market day. The gain marked the third consecutive day of increases for the stock.